NICOLA HANANIA to Leukocyte Count
This is a "connection" page, showing publications NICOLA HANANIA has written about Leukocyte Count.
Connection Strength
0.381
-
Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016 10; 4(10):781-796.
Score: 0.122
-
Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2025 Aug; 13(8):687-697.
Score: 0.056
-
Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials. Lancet Respir Med. 2025 Jun; 13(6):505-516.
Score: 0.055
-
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation. N Engl J Med. 2024 06 27; 390(24):2274-2283.
Score: 0.052
-
Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population. J Allergy Clin Immunol Pract. 2024 May; 12(5):1215-1224.e3.
Score: 0.051
-
Controversies in Allergy: Choosing a Biologic for Patients with Severe Asthma. J Allergy Clin Immunol Pract. 2022 02; 10(2):410-419.
Score: 0.044